Fungal keratitis by *Fusarium solani* treated with natamycin

**SANTIUSTE ROMÁN A, MONTERO HERNÁNDEZ M, LÓPEZ SÁNCHEZ EV, SOLER COMPANY E**
Hospital Arnau de Vilanova. Valencia (España)

**SUMMARY**
Fungal keratitis is a dangerous condition that can cause sight problems and even blindness. *Fusarium solani* is a kind of filamentous fungus which can cause this rare but important eye infection. Immunosuppressive therapy and use of contact lenses have increased the incidence. In this article we report two cases of *Fusarium solani* fungal keratitis in immunocompetent patients. They were first treated with different antimicrobial and antiparasitic eye drops (most of them formulated in the Pharmacy Service), until fungal infection was discovered. Natamycin was the election drug and was provided from the Pharmacy Service when purchased. Both patients improved from their pathology and fungal keratitis was resumed.

Key Words: Fungal keratitis, *Fusarium solani*, natamycin.

**CASE REPORT**

**Case 1**
A 38-year-old male patient, single-eye (right) and contact lens wearer attended the emergency services with a one-week history of red eye and foreign body feeling that was treated with ciprofloxacin 3 mg/ml and diclofenac 1 mg/ml eye drops. On examination, an edematized cornea with a sheltering central ulcer, Tyndall negative, was observed (Figure 1). Faced with the clinical worsening of the patient 7 days later (growth of the lesion, Tyndall positive – Figure 2) hospital admission was decided for sample collection and better control. The antibiotic treatment was modified for vancomycin and ceftazidime 50 mg/ml eye drops hourly. On the suspicion of infection by *Acanthamoeba* on the 10th day, treatment with chlorhexidine 0.2 mg/ml and hexamidine 15 mg/ml eye drops every 8 hours was added. Additionally, suspecting fungal infection, voriconazole 10 mg/ml eye drops hourly, were also added. This treatment was held until day 14, when culture revealed an infection by *Fusarium solani*. It was decided then to discontinue the antiparasitic treatment.
natamycin 50 mg/ml eye drops plus oral voriconazole therapy was started. On day 22, due to clinical improvement, the patient was discharged with topical voriconazole and natamycin. In subsequent reviews, debridement of the corneal necrotic material was required to improve ocular penetration of topical drugs. Antimicrobial eye drops treatment was spaced until discontinuation, remaining the patient with anti-inflammatory and corticosteroids eye drops. Over this 8-month period, although the antimicrobial treatment was effective, the patient’s visual acuity did not significantly improve, so it was decided to place an intracorneal lens to enhance vision. In the last medical examination, a relatively dense paracentral leukoma persisted in the center of the cornea (Figure 3).

**Case 2**

A 40-year-old male patient, with laser myopia surgery and contact lens wearer, was admitted due to outpatient treatment complications (ciprofloxacin 3 mg/ml, diclofenac 1 mg/ml). Upon admission, the patient presented a severe perillesional corneal edema and a large abscess in the cornea with a contracted pupil (Figure 4). Large-spectrum antibiotic treatment with vancomycin and ceftazidime 50 mg/ml eye drops hourly was started and corneal sample was collected. On day 2, against the lack of improvement, and suspecting *Acanthamoeba* infection, antiparasitic treatment with propamidine 1 mg/ml was added, followed by the addition of topical natamycin 50 mg/ml one day later, as it looked like a filamentous fungus was growing in the culture. On day 8, the growth of *Fusarium* was confirmed, so it was decided to withdraw propamidine; voriconazole 10 mg/ml eye drops was added, to cover, along with natamycin, this entire fungal gender. 2 days later (day 10), patient was discharged with vancomycin and ceftazidim eye drops every 6 hours and natamycin and voriconazole every 2 hours, as well as adjuvant treatment with cyclopentolate, phenylephrine and dexamethasone eye drops. On the 32nd day, *Fusarium solani* was finally isolated in the culture; antibiotic eye drops were then discontinued, but it was decided to maintain both polyene and azol eye drops. On the 50th day, the patient was definitely discharged; he presented corneal infiltrate, minimal perillesional edema and a small leukoma (Figure 5).

**DISCUSSION**

Fungal infections need to be promptly diagnosed. Treatment of infection with topical steroids is contraindicated, especially in the early stages, as they increase the proliferation and corneal penetration of the fungus.

The azoles and polyenes family stand out among the available antifungal therapies. Voriconazole and amphotericin B are just some of the options, but is natamycin the one that stands out as the treatment of choice, especially in the case of filamentous fungi, such as *Fusarium solani*. It presents low corneal toxicity, but its action is limited by its limited corneal penetration. It is advisable to combine it with desbridations in order to improve its penetration. The co-administration of natamycin and voriconazole increases the spectrum and even some studies suggest synergy, thus covering both filamentous and yeast infections. Many of these eye drops, not available commercially, have to be prepared by the Pharmacy Service. Alternatively, they can be purchased through different foreign medica-
tion suppliers. If the infection is of major severity, systemic and/or intravitreous antifungal treatment of broad-spectrum drugs such as amphotericin B or voriconazole will be additionally administered\(^2\). Where pharmacological treatment is not sufficiently successful, surgical intervention such as lamellar keratoplasty will be considered\(^2\).

In the two reported cases, patients improved their clinical situation from the onset of treatment with topical natamycin and voriconazole, subsequently discontinuing voriconazole when *Fusarium solani* was confirmed as the etiological agent.

**CONCLUSION**

An early diagnosis in fungal infections is essential to implement antifungal treatment in the shortest possible time. Treatment of *Fusarium solani* corneal fungal infections with natamycin topical, both alone or in combination with voriconazole, is effective and safe. Clinical improvement and reduction of the ulcer was observed. However, other studies would be required to confirm the effectiveness of this treatment for this sort of conditions. Access to this medication in Spain is restricted because it is not commercially available. Entails a long and tedious process, which could delay the onset of the treatment and may lead to a poorer resolution of the patient’s clinic. The importance of the hospital pharmacist’s intervention is evidenced, both in the elaboration and in the acquisition of the antimicrobial eye drops.

Conflict of interests: The authors declare no conflict of interests.

---

**Figure 5. Corneal infiltrate, minimal edema, small leukoma**

---

**BIBLIOGRAPHY**


